{"id":7262,"date":"2024-10-01T13:00:00","date_gmt":"2024-10-01T11:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/"},"modified":"2024-10-01T13:00:00","modified_gmt":"2024-10-01T11:00:00","slug":"alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/","title":{"rendered":"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB meddelar att doseringen av den sista patienten genomf\u00f6rts enligt plan i fas-1 studien med den l\u00e5ngtidsverkande dep\u00e5formuleringen av GLP-1 analogen liraglutid med PharmaShell\u00ae (NEX-22).<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Dosering av NEX-22 till patienter med Typ 2 diabetes slutf\u00f6rdes enligt plan i slutet av september p\u00e5 studiekliniken i Tyskland i den tredje och sista dosgruppen. Data fr\u00e5n de f\u00f6rsta tv\u00e5 dosgrupperna av PharmaShell formuleringen med liraglutid visar en f\u00f6rl\u00e4ngd fris\u00e4ttning med kontrollerad initial fris\u00e4ttning i blodet. Den l\u00e5ga initiala fris\u00e4ttningen \u00e4r positiv och kan bidra till att undvika vanliga gastrointestinala biverkningar vid ins\u00e4ttning av GLP-1 behandling, s\u00e5som illam\u00e5ende.<\/p>\n<p>\u201dV\u00e5ra interimdata fr\u00e5n studien st\u00e4rker v\u00e5r position i aff\u00e4rsdiskussioner, s\u00e4ger David Westberg, VD p\u00e5 Nanexa. Vi ser fram emot att presentera fullst\u00e4ndiga fas-1 studieresultat av NEX-22, som vi ser som en unik l\u00e5ngtidsverkande GLP-1 formulering med stor marknadspotential\u201d.<\/p>\n<p>Clinicaltrials.gov NCT06439056<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/11fe7e78-058c-4b6f-93dc-8926327f00fe\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan.pdf\" rel=\"noopener\" target=\"_blank\">Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB meddelar att doseringen av den sista patienten genomf\u00f6rts enligt plan i fas-1 studien med den l\u00e5ngtidsverkande dep\u00e5formuleringen av GLP-1 analogen liraglutid med PharmaShell\u00ae (NEX-22).<\/p>\n","protected":false},"template":"","class_list":["post-7262","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar att doseringen av den sista patienten genomf\u00f6rts enligt plan i fas-1 studien med den l\u00e5ngtidsverkande dep\u00e5formuleringen av GLP-1 analogen liraglutid med PharmaShell\u00ae (NEX-22).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\\\/\",\"name\":\"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-10-01T11:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/","og_locale":"sv_SE","og_type":"article","og_title":"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan - Nanexa AB","og_description":"Nanexa AB meddelar att doseringen av den sista patienten genomf\u00f6rts enligt plan i fas-1 studien med den l\u00e5ngtidsverkande dep\u00e5formuleringen av GLP-1 analogen liraglutid med PharmaShell\u00ae (NEX-22).","og_url":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/","url":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/","name":"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-10-01T11:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-i-nanexas-fas-1-studie-med-nex-22-doserade-enligt-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Alla patienter i Nanexas fas 1-studie med NEX-22 doserade enligt plan"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}